Autobio Diagnostics Co

Autobio Diagnostics Co Net Debt

The Net Debt of Autobio Diagnostics Co (603658.SS) as of Oct 17, 2026 is -3.79 B CNY. In the previous year, Net Debt was -4.15 B CNY — a change of -8.74% (higher).

Net Debt

-3.79 BCNY

YoY

-8.74%

Last updated:

Net Debt of Autobio Diagnostics Co is 2024 -3.79 B CNY. Net Debt of Autobio Diagnostics Co was 2023 -4.15 B CNY. It decreases by -8.74% higher compared to the previous year.

The Autobio Diagnostics Co Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2017
12.06 M CNY
Jan 1, 2018
38.35 M CNY
Jan 1, 2019
537.84 M CNY
Jan 1, 2020
-213.30 M CNY
Jan 1, 2021
-540.66 M CNY
Jan 1, 2022
-1.01 B CNY
Jan 1, 2023
-4.15 B CNY
Jan 1, 2024
-3.79 B CNY
The Autobio Diagnostics Co Net Debt history
YEARNet DebtYoY
-3.79 BCNY-8.74%
-4.15 BCNY+313.16%
-1.01 BCNY+85.90%
-540.66 MCNY+153.48%
-213.30 MCNY-139.66%
537.84 MCNY+1,302.49%
38.35 MCNY+217.86%
12.06 MCNY-112.00%
-100.53 MCNY+25.42%
-80.15 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Autobio Diagnostics Co Stock analysis

What does Autobio Diagnostics Co do? Autobio Diagnostics Co Ltd, listed on the Shanghai Stock Exchange under ticker 603658.SS, is a healthcare company based in Zhengzhou, China. The company specializes in the research, development, manufacturing, integration, service, and distribution of in vitro diagnostic reagents and instruments. With a workforce of 5,505 employees, Autobio Diagnostics went public on September 1, 2016. Its product portfolio includes immunodiagnostic reagents such as microplate chemiluminescence diagnostic reagents, enzyme-linked immunosorbent assay (ELISA) diagnostic reagents, magnetic particle chemiluminescence detection reagents, and colloidal diagnostic reagents. The company also offers microbiology detection products, including training detection reagents, susceptibility detection reagents, and rapid detection reagents. Device products encompass microplate readers, chemiluminescence immunoassay analyzers, and united testing analyzers. Autobio Diagnostics primarily serves domestic markets within China, focusing on providing diagnostic solutions for healthcare applications. The company's headquarters is located in Zhengzhou, Henan Province, and it operates within the healthcare sector, specifically in the health care industry. Its website, https://www.autobio.com.cn/, provides further information on its services and products. Autobio Diagnostics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Autobio Diagnostics Co stock

Net Debt of Autobio Diagnostics Co is -3.79 B CNY in 2024.

Net Debt of Autobio Diagnostics Co changed from -4.15 B CNY to -3.79 B CNY, representing a -8.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Autobio Diagnostics Co since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Autobio Diagnostics Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Autobio Diagnostics Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Autobio Diagnostics Co